Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0699790 (
colon cancer
)
28,837
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
PNAS-4
is a novel pro-apoptotic protein activated during the early response to DNA damage; however, the molecular mechanisms and pathways regulating
PNAS-4
expression in tumors are not well understood. We hypothesized that
PNAS-4
is a p53 down-stream target gene and designed this study. We searched online for putative p53-binding sites in the entire
PNAS-4
gene and did not find any corresponding information. In HCT116
colon cancer
cells, after being transfected with small interfering RNA to silence p53, the expressions of
PNAS-4
and other known p53 target gene (Apaf1, Bax, Fas and Dr5) were determined by real-time PCR. We found that
PNAS-4
was up-regulated while Apaf1, Bax, Fas and Dr5 were down-regulated. We then examined the expression of
PNAS-4
and p53 mutation in colorectal cancer patients.
PNAS-4
expressed both in colorectal cancers and normal tissues, but compared with paired control,
PNAS-4
was up-regulated in cancers (P=0.018).
PNAS-4
overexpression ratios were correlated to the p53 mutant status (P=0.001). The mean
PNAS-4
expression levels of p53 mutant homozygote group and heterozygote group were higher than that of p53 wild type group (P=0.013). The expression ratios of
PNAS-4
(every sample in relative to its paired normal mucosa) were different between negative lymph node metastasis (66% up-regulated, 34% down-regulated) and positive metastasis (42% up-regulated, 58% down-regulated). Taken together, these findings suggested that
PNAS-4
was not a p53 target, but overexpression of
PNAS-4
was correlated to p53 inactivity in colorectal cancer.
...
PMID:PNAS-4 expression and its relationship to p53 in colorectal cancer. 2155 70